Research Article
Serum Soluble TACI, a BLyS Receptor, Is a Powerful Prognostic Marker of Outcome in Chronic Lymphocytic Leukemia
Table 1
Patients’ characteristics at the time of diagnosis.
| Age, median (range) | 60 years (37–82) |
| | For BLyS measurements | For sTACI measurements |
| | 73 | 60 |
| | % |
| Sex, M/F | 61/39% | 66/34% | Binet stage | | | 1 | 59% | 60% | 2 | 34% | 32% | 3 | 7% | 8% | Lymphadenopathy | 60% | 60% | Splenomegaly | 18% | 15% | Haemoglobin <10 g/dL | 5.5% | 8.3% | Platelet counts <100 × /L | 2.7% | 3.3% | Abnormal LDH | 15% | 15% | BM infiltration >50% | 59% | 50% | β2-Microglobulin >3.5 mg/L | 30% (12/39 pts) | 27% (9/33 pts) | Abnormal κ-sFLC (normal 3.3–19.4 mg/L) | 30% (20/67 pts) | 30%(17/56 pts) | Abnormal λ-sFLC (normal 5.71–26.3 mg/L) | 8% (3/67 pts) | 5% (3/56 pts) |
|
|
FLC: free light chain.
|